Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 134, Issue 7
August 15 2019
Issue Cover

Table of Contents

BLOOD COMMENTARY

IMMUNOBIOLOGY AND IMMUNOTHERAPY
The case for CAR T-cell therapy in follicular lymphomas
Michael R. Bishop
View Articletitled, The case for CAR T-cell therapy in follicular lymphomas

PLENARY PAPER

Red Cells, Iron, and Erythropoiesis
Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD
Yunfeng Liu,Hui Zhong,Weili Bao,Avital Mendelson,Xiuli An,Patricia Shi,Stella T. Chou,Deepa Manwani,Karina Yazdanbakhsh
View Articletitled, Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD
Supplemental data

BLOOD SPOTLIGHT

An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma
Paul G. Murray,Lawrence S. Young
View Articletitled, An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma

REVIEW ARTICLE

The simpler, the better: oral arsenic for acute promyelocytic leukemia
CME Clinical Trials & Observations
Hong-Hu Zhu,Jiong Hu,Francesco Lo-Coco,Jie Jin
View Articletitled, The simpler, the better: oral arsenic for acute promyelocytic leukemia
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
Clinical Trials & Observations
Jeremy S. Abramson,Jon E. Arnason,Ann S. LaCasce,Robert Redd,Jeffrey A. Barnes,Lubomir Sokol,Robin Joyce,David Avigan,Donna Neuberg,Ronald W. Takvorian,Ephraim P. Hochberg,Celeste M. Bello
View Articletitled, Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
Supplemental data

HEMATOPOIESIS AND STEM CELLS

PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia–initiating cells
Tianyuan Hu,Kiyomi Morita,Matthew C. Hill,Yajian Jiang,Ayumi Kitano,Yusuke Saito,Feng Wang,Xizeng Mao,Kevin A. Hoegenauer,Kazuhiro Morishita,James F. Martin,P. Andrew Futreal,Koichi Takahashi,Daisuke Nakada
View Articletitled, PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia–initiating cells
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
Clinical Trials & Observations
Craig S. Sauter,Brigitte Senechal,Isabelle Rivière,Ai Ni,Yvette Bernal,Xiuyan Wang,Terence Purdon,Malloury Hall,Ashvin N. Singh,Victoria Z. Szenes,Sarah Yoo,Ahmet Dogan,Yongzeng Wang,Craig H. Moskowitz,Sergio Giralt,Matthew J. Matasar,Miguel-Angel Perales,Kevin J. Curran,Jae Park,Michel Sadelain,Renier J. Brentjens
View Articletitled, CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
Supplemental data
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
Clinical Trials & Observations Brief Report
Alexandre V. Hirayama,Jordan Gauthier,Kevin A. Hay,Jenna M. Voutsinas,Qian Wu,Barbara S. Pender,Reed M. Hawkins,Aesha Vakil,Rachel N. Steinmetz,Stanley R. Riddell,David G. Maloney,Cameron J. Turtle
View Articletitled, High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy

LYMPHOID NEOPLASIA

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study
Brief Report
Anne Quinquenel,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Luc-Matthieu Fornecker,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Rémi Letestu,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Loïc Ysebaert,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Carole Fleury,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Grégory Lazarian,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Marie-Sarah Dilhuydy,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Delphine Nollet,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Romain Guieze,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Pierre Feugier,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Damien Roos-Weil,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Lise Willems,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Anne-Sophie Michallet,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Alain Delmer,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Katia Hormigos,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Vincent Levy,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Florence Cymbalista,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group,Fanny Baran-Marszak,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group
View Articletitled, Prevalence of <em>BTK</em> and <em>PLCG2</em> mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study
Supplemental data

THROMBOSIS AND HEMOSTASIS

Acid sphingomyelinase plays a critical role in LPS- and cytokine-induced tissue factor procoagulant activity
Jue Wang,Usha R. Pendurthi,L. Vijaya Mohan Rao
View Articletitled, Acid sphingomyelinase plays a critical role in LPS- and cytokine-induced tissue factor procoagulant activity
Supplemental data

BLOOD WORK

Never judge a book by its cover: these neutrophils are not reactive!
Jean-Baptiste Rieu,Francois Vergez
View Articletitled, Never judge a book by its cover: these neutrophils are not reactive!
Oxidative hemolysis due to Wilson disease
Zhaodong Xu,Brian R. Berry
View Articletitled, Oxidative hemolysis due to Wilson disease

RETRACTION

Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117(8):2423-2432.
View Articletitled, Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. <em>Blood</em>. 2011;117(8):2423-2432.

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

Oral arsenic for acute promyelocytic leukemia
CME
View Articletitled, Oral arsenic for acute promyelocytic leukemia
All Issues

Advertisement intended for health care professionals

Mosunetuzumab next up to bat … is it a home run?
Novel CAR T cells to combat antigen escape in AML
Heme fuels venetoclax resistance in multiple myeloma
Introduction to a review series on mantle cell lymphoma: sands shifting in the darkness
Sequential epigenetic therapy in AML

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals